New Directions in Anti-angiogenesis Therapy in Metastatic Colorectal Cancer

Full Article

HH Loong, BBY Ma

Hong Kong J Radiol 2012;15(Suppl):S46-50

Mortality from metastatic colorectal cancer has declined over the past decade, partly due to improvement in survival secondary to incorporation of targeted biologics in the treatment paradigm. We are now witnessing a new wave of new therapeutic options that may further improve survival outcomes for patients with metastatic colorectal cancer. This review will discuss recently matured data on the treatment outcomes of new antiangiogenic targeted therapies in metastatic colorectal cancer and how they may affect the practice of oncology.





轉移性結直腸癌的死亡率在過去十年有下降的趨勢,部份原因是因為採納了生物製劑的標靶治療, 改善了存活率。我們現在見證了可以進一步改善轉移性結直腸癌患者的新一代治療。本文將會討論 抗血管新生標靶治療在轉移性結直腸癌治療結果的最新成熟數據,並探討這些數據如何影響腫瘤學 的實踐。